In addition, analysis of MM during treatment has shown that despite the influence of different treatment plans and response stages, MM patients with high expression of plasma cell SRRM2 still exhibit higher mSMART 3.0 risk stratification and cytogenetic abnormality risk. The gene discussed is SRRM2; the disease is Miyoshi myopathy.